Report on MCM industry released
The report, created from the results of a roundtable discussion between biosecurity experts, synthesizes information from analysts, academics and industry experts, according to BusinessWire.com.
"Companies working to develop and manufacture medicines and vaccines to protect the public from health emergencies, which are collectively referred to as medical countermeasures, face some inherent, but surmountable, challenges," Maureen Hardwick, the executive secretary of the Alliance for Biosecurity, said, BusinessWire.com reports.
A panel of 16 experts participated in the discussion, including Senator Richard Burr (R-N.C.) and the CEO of Emergent BioSolutions, Inc., Daniel Abdun-Nabi. Together, they shared their views on critical advancements in MCM development, lessons learned, and recommendations for future enterprises.
"Even in an environment of limited commercial market and regulatory challenges, there are opportunities," Michael Becker, a founder and senior Partner at MD Becker Partners, said, BusinessWire.com reports. "For example, biodefense companies have recognized that the expertise and knowledge gained by developing and manufacturing medical countermeasures can greatly benefit a company as they advance other commercial drug candidates."